{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:08:31Z","timestamp":1787969311130,"version":"build-2784847793"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review of the efficacy and safety of pravastatin use for prophylaxis and treatment of preeclampsia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis of clinical studies evaluating pravastatin for treatment and\/or prophylaxis of preeclampsia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data collection<\/jats:title>\n                    <jats:p>\n                      Two independent reviewers systematically searched data from PubMed, Scopus, Web of Science, Cochrane, Embase, and\n                      <jats:ext-link>clinicaltrials.gov<\/jats:ext-link>\n                      databases, for studies evaluating pravastatin for prevention of pre-eclampsia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fourteen studies were identified, including 1,570 pregnant women who received either pravastatin or placebo, published between 2003 and 2022. From these studies, 5 studies were identified for inclusion in the meta-analysis to evaluate the role of pravastatin use prior to 20 weeks of gestation, to prevent pre-eclampsia, Pravastatin treatment reduced the incidence of preeclampsia by 61% and premature birth by 45%. Among the newborns, there was a 45% reduction in intrauterine growth retardation (IUGR) in the treated group, as well as a 77% reduction in those receiving neonatal intensive care unit (NICU) admissions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prophylactic treatment with pravastatin appears to reduce risk of developing pre-eclampsia as well as potentially lowering risk of IUGR, preterm birth, and NICU admission in neonates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.1076372","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T23:42:51Z","timestamp":1673566971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Pravastatin in preeclampsia: A meta-analysis and systematic review"],"prefix":"10.3389","volume":"9","author":[{"given":"Bal\u00e1zs","family":"M\u00e9sz\u00e1ros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel S\u00e1ndor","family":"Veres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Nagyist\u00f3k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik\u00f3","family":"Somogyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kl\u00e1ra","family":"Rosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Kukor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/HYPERTENSIONAHA.117.10803","article-title":"International society for the study of hypertension in pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice.","volume":"72","author":"Brown","year":"2018","journal-title":"Hypertension."},{"key":"B2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0140-6736(10)60279-6","article-title":"Pre-eclampsia.","volume":"376","author":"Steegers","year":"2010","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f6564","article-title":"Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis.","volume":"347","author":"Ananth","year":"2013","journal-title":"BMJ."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14875","article-title":"Maternal microbiome in preeclampsia pathophysiology and implications on offspring health.","volume":"9","author":"Ishimwe","year":"2021","journal-title":"Physiol Rep."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-020-1026-8","article-title":"Novel interventions for the prevention of preeclampsia.","volume":"22","author":"Ma\u2019ayeh","year":"2020","journal-title":"Curr Hypertens Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1515\/jpm-2017-0109","article-title":"Is pravastatin a milestone in the prevention and treatment of preeclampsia?","volume":"46","author":"Gajzlerska-Majewska","year":"2018","journal-title":"J Perinat Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2174\/1389201019666180925115559","article-title":"Angiogenic imbalance as a contributor of preeclampsia.","volume":"19","author":"Dymara-Konopka","year":"2018","journal-title":"Curr Pharm Biotechnol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/jch.12541","article-title":"Low-dose aspirin for preventing preeclampsia and its complications: a meta-analysis.","volume":"17","author":"Xu","year":"2015","journal-title":"J Clin Hypertens."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l2381","article-title":"Pre-eclampsia: pathophysiology and clinical implications.","volume":"366","author":"Burton","year":"2019","journal-title":"BMJ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6284","DOI":"10.2174\/138161212803832335","article-title":"Statin therapy.","volume":"18","author":"Koch","year":"2012","journal-title":"Curr Pharm Des."},{"key":"B11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nrcardio.2013.209","article-title":"Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics.","volume":"11","author":"Mikhailidis","year":"2014","journal-title":"Nat Rev Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"S1171","DOI":"10.1016\/j.ajog.2020.08.040","article-title":"The role of statins in the prevention of preeclampsia.","volume":"226","author":"Smith","year":"2022","journal-title":"Am J Obstet Gynecol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-019-2507-0","article-title":"Pravastatin induces NO synthesis by enhancing microsomal arginine uptake in healthy and preeclamptic placentas.","volume":"19","author":"P\u00e1ncz\u00e9l","year":"2019","journal-title":"BMC Pregnancy Childbirth."},{"key":"B14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1556\/650.2020.31670","article-title":"A pravasztatin hat\u00e1sa tetrahidrobiopterin-\u00e9rz\u00e9keny \u00e9s -rezisztens praeeclampsi\u00e1s placent\u00e1k NO-szint\u00e1z-aktivit\u00e1s\u00e1ra [Effect of pravastatin on tetrahydrobiopterin-sensitive and -resistant NO synthase activity of preeclamptic placentas].","volume":"161","author":"P\u00e1ncz\u00e9l","year":"2020","journal-title":"Orv Hetil."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJM200404083501524","article-title":"Central nervous system and limb anomalies in case reports of first-trimester statin exposure.","volume":"350","author":"Edison","year":"2004","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.41321","article-title":"Perinatal outcomes after statin exposure during pregnancy.","volume":"4","author":"Chang","year":"2021","journal-title":"JAMA Netw Open."},{"key":"B17","first-page":"1993","article-title":"Familial hypercholesterolemia.","author":"Ison","year":"","journal-title":"GeneReviews<sup>\u00ae<\/sup> [Internet]."},{"key":"B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.09.010","article-title":"A systematic review and meta-analysis on the effects of statins on pregnancy outcomes.","volume":"336","author":"Vahedian-Azimi","year":"2021","journal-title":"Atherosclerosis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.preghy.2020.03.004","article-title":"Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction.","volume":"20","author":"de Alwis","year":"2020","journal-title":"Pregnancy Hypertens."},{"key":"B20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2174\/1389557518666181015151350","article-title":"Radicals, oxidative\/nitrosative stress and preeclampsia.","volume":"19","author":"Taysi","year":"2019","journal-title":"Mini Rev Med Chem."},{"key":"B21","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1556\/oh.2010.29012","article-title":"A nitrog\u00e9n-monoxid-szint\u00e9zis zavarai praeeclampsi\u00e1ban [Nitric oxide and preeclampsia].","volume":"151","author":"Kukor","year":"2010","journal-title":"Orv Hetil."},{"key":"B22","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1556\/OH.2012.29415","article-title":"A praeeclampsia k\u00f3r\u00e9lettana a k\u00e9tl\u00e9pcs\u0151s modell t\u00fckr\u00e9ben [The pathophysiology of preeclampsia in view of the two-stage model].","volume":"153","author":"Alasztics","year":"2012","journal-title":"Orv Hetil."},{"key":"B23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.placenta.2014.12.007","article-title":"Insulin restores L-arginine transport requiring adenosine receptors activation in umbilical vein endothelium from late-onset preeclampsia.","volume":"36","author":"Salsoso","year":"2015","journal-title":"Placenta."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-016-0902-3","article-title":"Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta.","volume":"16","author":"Brownfoot","year":"2016","journal-title":"BMC Pregnancy Childbirth."},{"key":"B25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jog.12876","article-title":"Simvastatin inhibits oxidative stress via the activation of nuclear factor erythroid 2-related factor 2 signaling in trophoblast cells.","volume":"42","author":"Chigusa","year":"2016","journal-title":"J Obstet Gynaecol Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1177\/1933719116678693","article-title":"Simvastatin alleviates pathology in a rat model of preeclampsia involving ERK\/MAPK pathway.","volume":"24","author":"Dong","year":"2017","journal-title":"Reprod Sci."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12071121","article-title":"Effect of pravastatin and simvastatin on the reduction of cytochrome C.","volume":"12","author":"Csom\u00f3","year":"2022","journal-title":"J Pers Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1161\/HYPERTENSIONAHA.111.00226","article-title":"Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension.","volume":"61","author":"Bauer","year":"2013","journal-title":"Hypertension."},{"key":"B29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/OGX.0000000000000522","article-title":"Pravastatin for preventing and treating preeclampsia: a systematic review.","volume":"73","author":"Esteve-Valverde","year":"2018","journal-title":"Obstet Gynecol Surv."},{"key":"B30","author":"Higgins","year":"2022","journal-title":"Cochrane handbook for systematic reviews of interventions."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate.","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? use and avoidance of continuity corrections in meta-analysis of sparse data.","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-25","article-title":"The hartung-knapp-sidik-jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard dersimonian-laird method.","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol."},{"key":"B34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.6028\/jres.087.022","article-title":"Consensus values and weighting factors.","volume":"87","author":"Paule","year":"1982","journal-title":"J Res Nat Bureau Stand."},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1201\/9781003107347","author":"Harrer","year":"2021","journal-title":"Doing meta-analysis with R: a hands-on guide."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med."},{"key":"B37","year":"2022","journal-title":"R: a language and environment for statistical computing."},{"key":"B38","author":"Schwarzer","year":"2022","journal-title":"Meta: general package for meta-analysis."},{"key":"B39","article-title":"Pravastatin kezel\u00e9s hat\u00e1sa preeclampsi\u00e1s terhess\u00e9gekben \u2013 metaanal\u00edzis.","volume":"2","author":"Nagyist\u00f3k","year":"2020","journal-title":"Orvosk\u00e9pz\u00e9s."},{"key":"B40","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B41","doi-asserted-by":"publisher","first-page":"720.e1","DOI":"10.1016\/j.ajog.2015.12.038","article-title":"Eunice kennedy shriver national institute of child health and human development obstetric-fetal pharmacology research units network. safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial.","volume":"214","author":"Costantine","year":"2016","journal-title":"Am J Obstet Gynecol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"666.e1","DOI":"10.1016\/j.ajog.2021.05.018","article-title":"Eunice kennedy shriver national institute of child health and human development obstetric-fetal pharmacology research centers (OPRC) network, Bethesda, MD. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.","volume":"225","author":"Costantine","year":"2021","journal-title":"Am J Obstet Gynecol."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1055\/a-1673-5603","article-title":"INOVASIA study: a randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1\/PlGF levels.","author":"Akbar","year":"2021","journal-title":"Am J Perinatol."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1055\/a-1798-1925","article-title":"INOVASIA study: a multicenter randomized clinical trial of pravastatin to prevent preeclampsia in high-risk patients.","author":"Akbar","year":"2022","journal-title":"Am J Perinatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"8055","DOI":"10.1080\/14767058.2021.1940940","article-title":"Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study.","volume":"35","author":"Kupferminc","year":"2022","journal-title":"J Matern Fetal Neonatal Med."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174246","article-title":"Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors.","volume":"20","author":"Tomimatsu","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1172\/JCI86957","article-title":"Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy.","volume":"126","author":"Lefkou","year":"2016","journal-title":"J Clin Invest."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1055\/s-0040-1713651","article-title":"Evaluating the effect of pravastatin in early-onset fetal growth restriction: a nonrandomized and historically controlled pilot study.","volume":"38","author":"Mendoza","year":"2021","journal-title":"Am J Perinatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.121.053963","article-title":"Pravastatin versus placebo in pregnancies at high risk of term preeclampsia.","volume":"144","author":"D\u00f6bert","year":"2021","journal-title":"Circulation."},{"key":"B50","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/1471-0528.16013","article-title":"Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial.","volume":"127","author":"Ahmed","year":"2020","journal-title":"BJOG."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114217","article-title":"Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism.","volume":"182","author":"Lefkou","year":"2020","journal-title":"Biochem Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2020.106824","article-title":"Pravastatin plus L-arginine prevents adverse pregnancy outcomes in women with uteroplacental vascular dysfunction.","volume":"137","author":"Jurisic","year":"2021","journal-title":"Vascul Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1161\/HYPERTENSIONAHA.114.03115","article-title":"Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin.","volume":"63","author":"Lefkou","year":"2014","journal-title":"Hypertension."},{"key":"B54","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1161\/HYPERTENSIONAHA.115.05445","article-title":"Effects of pravastatin on human placenta, endothelium, and women with severe preeclampsia.","volume":"66","author":"Brownfoot","year":"2015","journal-title":"Hypertension."},{"key":"B55","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/jcpt.13590","article-title":"Pravastatin concentrations in maternal serum, umbilical cord serum, breast milk and neonatal serum during pregnancy and lactation: a case study.","volume":"47","author":"Saito","year":"2022","journal-title":"J Clin Pharm Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pd.5645","article-title":"Aspirin for prevention of preeclampsia and fetal growth restriction.","volume":"40","author":"Loussert","year":"2020","journal-title":"Prenat Diagn."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1182\/blood-2011-11-391383","article-title":"Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.","volume":"119","author":"Martinelli","year":"2012","journal-title":"Blood."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s40265-017-0823-0","article-title":"Aspirin for prevention of preeclampsia.","volume":"77","author":"Atallah","year":"2017","journal-title":"Drugs."},{"key":"B59","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia.","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"580.e1","DOI":"10.1016\/j.ajog.2019.02.034","article-title":"Aspirin delays the development of preeclampsia.","volume":"220","author":"Wright","year":"2019","journal-title":"Am J Obstet Gynecol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000341937","article-title":"Arginine and citrulline supplementation in sports and exercise: ergogenic nutrients?","volume":"59","author":"Sureda","year":"2012","journal-title":"Med Sport Sci."},{"key":"B62","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1160\/TH16-02-0169","article-title":"LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis.","volume":"116","author":"Mastrolia","year":"2016","journal-title":"Thromb Haemost."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1753","article-title":"Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies.","volume":"353","author":"Bartsch","year":"2016","journal-title":"BMJ."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223888","article-title":"Increased BMI has a linear association with late-onset preeclampsia: a population-based study.","volume":"14","author":"Robillard","year":"2019","journal-title":"PLoS One."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijgo.12802","article-title":"The international federation of gynecology and obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention.","volume":"145","author":"Poon","year":"2019","journal-title":"Int J Gynaecol Obstet."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154555","article-title":"Results of a five-year experience in first trimester preeclampsia screening.","volume":"11","author":"Capriglione","year":"2022","journal-title":"J Clin Med."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-022-04514-4","article-title":"Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia.","volume":"22","author":"Huang","year":"2022","journal-title":"BMC Pregnancy Childbirth."},{"key":"B68","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/uog.22093","article-title":"Screening for pre-eclampsia at 11-13 weeks\u2019 gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.","volume":"56","author":"Mazer Zumaeta","year":"2020","journal-title":"Ultrasound Obstet Gynecol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/14767058.2018.1495191","article-title":"Preeclampsia and the challenge of early prediction: reality or utopia? State of art and critical review of literature.","volume":"33","author":"Capriglione","year":"2020","journal-title":"J Matern Fetal Neonatal Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1684\/abc.2016.1158","article-title":"Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia.","volume":"74","author":"Lecarpentier","year":"2016","journal-title":"Ann Biol Clin."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1002\/ajmg.a.32493","article-title":"National birth defects prevention study. Maternal exposure to statins and risk for birth defects: a case-series approach.","author":"Petersen","year":"2008","journal-title":"Am J Med Genet A."},{"key":"B72","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.reprotox.2018.12.002","article-title":"Aspirin pre-treatment modulates ozone-induced fetal growth restriction and alterations in uterine blood flow in rats.","volume":"83","author":"Miller","year":"2019","journal-title":"Reprod Toxicol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/OGX.0000000000000747","article-title":"Preeclampsia among african american pregnant women: an update on prevalence, complications, etiology, and biomarkers.","volume":"75","author":"Zhang","year":"2020","journal-title":"Obstet Gynecol Surv."},{"key":"B74","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1053\/j.semperi.2009.02.010","article-title":"The global impact of pre-eclampsia and eclampsia.","volume":"33","author":"Duley","year":"2009","journal-title":"Semin Perinatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1076372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T23:42:59Z","timestamp":1673566979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1076372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":74,"alternative-id":["10.3389\/fmed.2022.1076372"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1076372","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"article-number":"1076372"}}